Literature DB >> 1382904

The role of O-antigen polysaccharide in the activation of neutrophils by lipopolysaccharides of Salmonella species.

O Rasool1, N A Nnalue, C Jarstrand.   

Abstract

Activation of neutrophils by lipid A, O-antigen polysaccharides (PS) and smooth lipopolysaccharides (LPS) isolated from Salmonella choleraesuis (O-6,7) and Salmonella typhimurium (O-4,5,12) was investigated. The methods used were assays for lysozyme release and for nitroblue tetrazolium (NBT) reduction which measures the level of oxidative metabolism of neutrophils. LPS from both species stimulated neutrophils to the same extent in the presence of autologous plasma. In the absence of plasma only the O-6,7 LPS activated neutrophils. Lipid A or PS isolated from both LPS either did not activate neutrophils or did so only at very high concentrations when tested in the presence of plasma; in the absence of plasma no activation occurred. The data indicate that both PS and lipid A segments of LPS are required for activation of neutrophils by LPS. We also deduce that plasma, probably complement, is required for the interaction of some LPS, e.g. O-4,5,12 with neutrophils whereas other LPS, e.g. O-6,7 can interact directly and activate neutrophils.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382904      PMCID: PMC1554533          DOI: 10.1111/j.1365-2249.1992.tb05832.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  13 in total

Review 1.  Ligand-receptor dynamics and signal amplification in the neutrophil.

Authors:  L A Sklar
Journal:  Adv Immunol       Date:  1986       Impact factor: 3.543

2.  Mechanism of endotoxin interaction with human leucocytes.

Authors:  M J Cline; K L Melmon; W C Davis; H E Williams
Journal:  Br J Haematol       Date:  1968-12       Impact factor: 6.998

3.  Phagocytosis of bacteria by macrophages: changing the carbohydrate of lipopolysaccharide alters interaction with complement and macrophages.

Authors:  C J Liang-Takasaki; P H Mäkelä; L Leive
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

4.  Standardisation of the nitroblue-tetrazolium test.

Authors:  D Merzbach; N Obedeanu
Journal:  J Med Microbiol       Date:  1975-05       Impact factor: 2.472

5.  Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b.

Authors:  G D Ross; J A Cain; P J Lachmann
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

6.  Endotoxin-binding substances from human leukocytes and platelets.

Authors:  G F Springer; J C Adye
Journal:  Infect Immun       Date:  1975-11       Impact factor: 3.441

7.  Effect of Brucella abortus lipopolysaccharide on oxidative metabolism and lysozyme release by human neutrophils.

Authors:  O Rasool; E Freer; E Moreno; C Jarstrand
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

8.  High-density lipoproteins inhibit the bacterial lipopolysaccharide mediated increase in oxidative metabolism and lysozyme release by neutrophilic granulocytes in vitro.

Authors:  A Wiernik; L A Carlson; C Jarstrand
Journal:  J Clin Lab Immunol       Date:  1986-11

9.  Salmonellae activate complement differentially via the alternative pathway depending on the structure of their lipopolysaccharide O-antigen.

Authors:  C J Liang-Takasaki; N Grossman; L Leive
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

10.  Expression of a mannosyl-fucosyl receptor for endocytosis on cultured primary macrophages and their hybrids.

Authors:  P Stahl; S Gordon
Journal:  J Cell Biol       Date:  1982-04       Impact factor: 10.539

View more
  1 in total

1.  Similarity to peroxisomal-membrane protein family reveals that Sinorhizobium and Brucella BacA affect lipid-A fatty acids.

Authors:  Gail P Ferguson; Anup Datta; John Baumgartner; R Martin Roop; Russ W Carlson; Graham C Walker
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-24       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.